Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

作者：Kaitlin Annunzio, Eric McLaughlin, Timothy Voorhees, Lauren Shea, Nuttavut Sumransub, Ashley Rose, Adam J. Olszewski, Neil A. Bailey, Krish Patel, Tamara K. Moyo, Farrukh T. Awan, Gulrayz Ahmed, Natalie S. Grover, Adam Z. Adika, Erica L. Andres, Muhammad Salman Faisal, Beth Christian, Jacob Anna, Steven M. Bair, Nicholas D. Kendsersky, Colin Thomas, Pallawi Torka, Jakub Svoboda, Jordan S. Carter, Mehdi Hamadani, Hayder Saeed, Sanjal H. Desai, Andrew M. Evens, Narendranath Epperla · 发表于：Blood · 年份：2023 · DOI：10.1182/blood-2023-182389 · 被引用次数：5 · 研究领域：Lymphoma Diagnosis and Treatment、Cardiac tumors and thrombi

Introduction The cornerstone for management of newly diagnosed patients (pts) with cHL is an anthracycline (AC) based chemotherapy (chemo) regimen. There are a paucity of data available regarding treatment patterns and outcomes for cHL pts with low EF. Furthermore, cHL pts with low EF are typically excluded from clinical trials limiting our understanding on management of these pts. Methods This was a multicenter retrospective cohort study evaluating pts with newly diagnosed cHL with low EF from 16 US medical centers. Eligible pts included adults diagnosed after 1/1/2010 with pretreatment EF of <50% on echocardiogram. Pts who developed reduced EF during or after first-line treatment were excluded. Based on EF, pts were divided into 2 groups (gp): <45% (gp 1) and 45-49% (gp 2). First-line treatment was categorized into AC based and non-AC based therapies. Primary outcome was progression-free survival (PFS). Secondary outcomes included response rates to first-line therapy and overall survival (OS). Time to event endpoints were evaluated by Kaplan-Meier and Cox proportional hazard methods. Results The study included 69 pts with a median age of 55 yrs (21-88), 74% males, and performance status (PS) of ECOG 0-1 in 65%. There were 37 (54%) pts in gp 1 and 32 (46%) in gp 2. 39 pts received AC and 30 received non-AC based therapies. Pts in the AC group were significantly younger (median age, 46 vs 64 yrs), had higher proportion with EF of 45-49% (72% vs 13%) & ECOG P...